non-small cell lung cancer
Conditions
Interventions
control group:Placebo
Sponsors
Guang'anmen Hospital, China Academy of Chinese Medical Sciences.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Postoperative patients with NSCLC in stage I, confirmed by pathology or cytology; 2. Enrolled within 2 weeks after surgery; 3. The surgical mode is single hole thoracoscopic lobectomy 4. Aged 18-75 years; 5. ECOG 0-2 scores; 6. The expected survival time equal or greater than 6 months; 7. NEUT >1.5 x 10^9/L, PLT > 100 x 10^9/L, Hb > 9.0g/dl, TBIL normal or > 1.5 ULN; AST (SGOT)ALT (SGPT) < 2.5 ULN, CRE < 1.5 ULN.
Exclusion criteria
Exclusion criteria: 1. Patients who received neoadjuvant chemotherapy before surgery; 2. Patients who plan to receive other treatments such as radiotherapy, chemotherapy, targeted therapy, etc.within 1 month after surgery; 3. Severe complications like pulmonary embolism, respiratory failure and myocardial infarction occurred during the perioperative period; 4. In other clinical trials; 5. Pregnant or lactating patients; 6. Having a history of mental illness that is difficult to control; 7. Allergic to study drugs; 8. Cannot understand and refuse to sign informed consent; 9. Cannot cooperate with the scale data collection.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| symptom threshold events reduction rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| mean symptom interference;quality of life;lung function; | — |
Countries
China
Contacts
Public ContactWei Hou
Guang'anmen Hospital, China Academy of Chinese Medical Sciences
Outcome results
None listed